| __timestamp | Bristol-Myers Squibb Company | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3932000000 | 21226345 |
| Thursday, January 1, 2015 | 3909000000 | 139626 |
| Friday, January 1, 2016 | 4946000000 | 93831530 |
| Sunday, January 1, 2017 | 6066000000 | 79419009 |
| Monday, January 1, 2018 | 6547000000 | 368673 |
| Tuesday, January 1, 2019 | 8078000000 | 477121 |
| Wednesday, January 1, 2020 | 11773000000 | 1895029 |
| Friday, January 1, 2021 | 9940000000 | 8034589 |
| Saturday, January 1, 2022 | 10137000000 | 20443000 |
| Sunday, January 1, 2023 | 10693000000 | 33745000 |
| Monday, January 1, 2024 | 11949000000 |
Cracking the code
In the ever-evolving pharmaceutical landscape, understanding cost structures is crucial. Bristol-Myers Squibb Company, a titan in the industry, has consistently demonstrated robust cost management. From 2014 to 2023, their cost of revenue surged by approximately 172%, peaking in 2020. This reflects their strategic investments and operational efficiencies.
In contrast, Intra-Cellular Therapies, Inc., a burgeoning player, has shown a more volatile trajectory. Their cost of revenue increased by over 1,500% during the same period, highlighting their aggressive growth strategy. Despite the disparity in scale, both companies underscore the dynamic nature of pharmaceutical economics.
While Bristol-Myers Squibb's cost of revenue is significantly higher, Intra-Cellular's rapid growth rate is noteworthy. This comparison offers a glimpse into the diverse strategies within the pharmaceutical sector.
Eli Lilly and Company vs Bristol-Myers Squibb Company: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down AstraZeneca PLC and Bristol-Myers Squibb Company's Expenses
Cost of Revenue Comparison: Sanofi vs Intra-Cellular Therapies, Inc.
Comparing Cost of Revenue Efficiency: Bristol-Myers Squibb Company vs CRISPR Therapeutics AG
Comparing Cost of Revenue Efficiency: Bristol-Myers Squibb Company vs Bausch Health Companies Inc.
Cost of Revenue: Key Insights for Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Bristol-Myers Squibb Company vs Wave Life Sciences Ltd.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Bristol-Myers Squibb Company vs Evotec SE
Comparing Cost of Revenue Efficiency: Bristol-Myers Squibb Company vs Viridian Therapeutics, Inc.
Intra-Cellular Therapies, Inc. vs Sarepta Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs HUTCHMED (China) Limited
Intra-Cellular Therapies, Inc. vs Wave Life Sciences Ltd.: Efficiency in Cost of Revenue Explored